February 11, 2013
Posted by on
Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to proceed by the effective date of the agreement. Cangene has acquired a hemophilia compound from the remaining assets of Inspiration Biopharmaceuticals, which is undergoing bankruptcy proceedings. Cangene paid $5.9 million for the compound. Also in the news, Stem Cell Therepuetics will undergo a plan of arrangement with Trillium Therepeutics, where the two companies will effectively be merged and continue to operate under Stem Cell’s name.
Of course, there was considerably more activity this week, so click through to get the full story!
Read more of this post
June 18, 2009
Posted by on
Despite the skepticism expressed in the New York Times article last week, the efforts by various jurisdictions to attract biotech business continues apace.
For one, the Mayor of Jerusalem announced a $25 million program to build infrastructure and human resources for a biomedical research park at Hebrew University School of Medicine. Of course, they’ll have to do it without Rafi.
And at least one jursidiction — Wisconsin – seems to have been having some recent successes:
Stay tuned to the money=jobs post on our Biotech Bailout page for more.
June 1, 2009
Posted by on
Rafi Hofstein has joined MaRS Innovation as its new CEO. He was previously the President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem, and since 2005, Chair of Hadasit BioHolding Ltd. (TASE: HBL). In this role, he oversaw:
the commercialization of intellectual property emerging from the Hadassah Medical Organization, clinical trials with industry partners, as well as the launch, development and strategic oversight of a series of medical devices, biomedicine and diagnostic equipment spin-off companies.
He has Ag experience too, having been the Vice President Business Development for Ecogen, Inc., a subsidiary of Monsanto. He was also at the helm of Mindsense Biosystems, and has his Ph.D. from Weizmann.
Well, Dr. Hofstein, welcome to Canada and to our little University Avenue (and Bay Street) slice of innovation heaven.
For those who aren’t in the know, here’s the scoop on MaRS Innovation:
MaRS Innovation provides an integrated commercialization platform that harnesses the economic potential of the exceptional discovery pipeline of 14 leading Toronto academic institutions. MaRS Innovation is a non-profit organization with an independent industry-led Board of Directors, funded through the Government of Canada’s CECR Program and contributions of its member institutions, as well as support from the Province of Ontario.